A RAS platform winner moving toward a commercial launch
- Daraxonrasib showed a major Phase 3 win in second-line pancreatic cancer, achieving a median overall survival of 13.2 months versus 6.7 months for chemotherapy.
- The FDA accepted the new drug application for daraxonrasib, and an expanded access program has already reached over 2,000 patients.
- Early combination data for two other drugs in lung cancer showed response rates above 80 percent, validating the broader pipeline.
- The company holds a strong cash position after raising about $2.1 billion in early 2026 to fund its clinical trials.
- Operating cash burn is very high, driven by the expanding late-stage clinical trials across multiple cancer types.
One trial changed the story
Revolution Medicines is no longer only a platform story. In April 2026, its lead drug daraxonrasib reported positive Phase 3 results in second-line pancreatic ductal adenocarcinoma, a hard-to-treat cancer often shortened to PDAC. The trial showed median overall survival of 13.2 months for daraxonrasib versus 6.7 months for chemotherapy. Patients on the drug lived much longer in this study, and the result was very unlikely to be random.
That result gave the company a clear path to file for approval. The FDA has now accepted the new drug application for daraxonrasib in second-line PDAC, and the European Medicines Agency initiated a phased review. Following these milestones, an expanded access treatment protocol for daraxonrasib has seen immense demand, providing the drug to over 2,000 patients.
The rest of the pipeline is also showing promise. Recent data for elironrasib and zoldonrasib in combination therapies for lung cancer achieved response rates over 80 percent, which supports starting more large trials. To fund this, Revolution completed stock and convertible note offerings in early 2026, yielding about $2.1 billion in net proceeds.
The main caution is that one win does not guarantee success in every cancer type. The stock depends on Phase 3 outcomes in lung cancer, first-line PDAC, and combinations. Spending is very high, with 2026 operating expenses guided upward of $2.1 billion, and new issues like the Erasca intellectual property dispute could weigh on the story.
No drug sales yet
Revolution Medicines is a clinical-stage biotech. That means it does not yet sell an approved medicine. Its value comes from the chance that its drug candidates win approval, reach patients, and become commercial products.
The company builds small-molecule cancer drugs using structure-based design, chemical biology, and cancer pharmacology. Its main focus is RAS(ON) inhibitors. These drugs aim at the active form of RAS, instead of the inactive form targeted by older approaches.
Past revenue came from collaboration agreements that included upfront payments and research reimbursements. Today, partnerships mainly help test combinations, such as the Bristol Myers Squibb study of daraxonrasib with navlimetostat and the Synnovation plan to test a PARP inhibitor with daraxonrasib.
The model relies on clinical success. It breaks if the drugs fail late trials, regulators reject the filings, manufacturing cannot scale, or launch uptake is weak. Even with a large cash balance, the company must successfully transition from research to commercial sales.
A pipeline built around active RAS
Daraxonrasib, RMC-6236
This oral multi-selective RAS(ON) inhibitor is the lead program. The FDA has accepted its new drug application for second-line PDAC.
Elironrasib, RMC-6291
This oral G12C-selective RAS(ON) inhibitor has FDA Breakthrough Therapy Designation for mutated lung cancer after prior therapies.
Zoldonrasib, RMC-9805
This oral G12D-selective RAS(ON) inhibitor has FDA Breakthrough Therapy Designation for previously treated mutated lung cancer.
RMC-5127
This G12V-selective RAS(ON) inhibitor is in a first-in-human dose escalation trial, providing a fourth clinical-stage program.
Next-generation RAS(ON) inhibitors
These preclinical drugs are designed to overcome RAS-driven drug resistance. The company expects to start human trials in late 2026.
RAS companion inhibitors
This group includes SHP2, mTORC1, and SOS1 inhibitors. Further development is subject to portfolio prioritization.
Spending shows the real focus
Revolution reports as one research and development business, not as separate commercial segments. The mix below uses 2025 third-party R&D program spending, calculated across the listed program categories.
What could still go wrong
Regulatory approval and launch delays
High impact · Medium oddsThe FDA accepted the new drug application for daraxonrasib in second-line PDAC, but approval is not automatic. The FDA still needs to review the safety profile and manufacturing plans. Any delay would push out the first possible product revenue.
Next Phase 3 trials disappoint
High impact · Medium oddsThe bull case assumes daraxonrasib and other drugs work beyond second-line PDAC. Trials in lung cancer, first-line PDAC, and combinations are costly and not guaranteed to match the lead result. A miss would shrink the market opportunity.
Cash burn stays very high
Medium impact · High oddsThe company has a large cash balance, but spending is also large. Management guided for 2026 GAAP operating expenses between $2.1 billion and $2.2 billion. Launch preparation will add more cost.
Erasca IP dispute expands
Medium impact · Medium oddsIn April 2026, Revolution disclosed intellectual property matters involving Erasca. A dispute could become expensive and distract management. It could also lead to counterclaims that challenge the company's patent position.
BIOSECURE Act supply chain pressure
Medium impact · Medium oddsThe BIOSECURE Act could limit work with certain China-linked biotechnology companies. Revolution uses third-party manufacturing and has relationships with entities in China. Changing suppliers could cost time and money.
In one breath
What does Revolution Medicines do?
Revolution Medicines develops targeted cancer drugs for tumors driven by RAS mutations. Its main approach is to block RAS in its active state.
Does Revolution Medicines have an approved drug?
No. It is a clinical-stage company. However, the FDA has accepted the new drug application for daraxonrasib in second-line pancreatic cancer.
Why was the RASolute 302 trial important?
It showed a clear survival benefit for daraxonrasib versus chemotherapy in second-line PDAC. The median overall survival was 13.2 months versus 6.7 months.
What is the biggest risk for RVMD stock?
The biggest risk is that more late-stage trials fail or regulators do not approve daraxonrasib. High cash burn, patent litigation, and supply chain rules are also key risks.
